Haleon’s (HLN) “Hold” Rating Reaffirmed at HSBC

Haleon (NYSE:HLN)‘s stock had its “hold” rating reissued by research analysts at HSBC in a note issued to investors on Wednesday.

Several other brokerages also recently issued reports on HLN. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Trading Up 0.9 %

NYSE HLN opened at $10.68 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $48.33 billion, a PE ratio of 31.40, a P/E/G ratio of 2.82 and a beta of 0.28. The stock has a 50-day simple moving average of $9.61 and a 200 day simple moving average of $9.84. Haleon has a 12 month low of $7.89 and a 12 month high of $10.80.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Research analysts forecast that Haleon will post 0.43 EPS for the current year.

Institutional Trading of Haleon

A number of hedge funds and other institutional investors have recently bought and sold shares of HLN. Sierra Ocean LLC purchased a new position in shares of Haleon in the fourth quarter worth about $26,000. Versant Capital Management Inc boosted its position in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Haleon in the 4th quarter worth approximately $35,000. Toronto Dominion Bank raised its position in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in shares of Haleon in the 4th quarter valued at approximately $39,000. Institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.